Published in BMC Dermatol on February 13, 2015
Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells. Biomed Res Int (2016) 0.76
Development of Photoonycholysis with Vandetanib Therapy. Skin Appendage Disord (2016) 0.75
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res (2002) 4.16
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol (2008) 1.53
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res (2005) 1.38
Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf (2002) 1.27
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol (2009) 1.23
ZD6474--clinical experience to date. Br J Cancer (2005) 1.23
Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf (2007) 1.03
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab (2012) 0.96
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol (2012) 0.94
Severe photosensitivity reaction to vandetanib. J Clin Oncol (2009) 0.92
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther (2009) 0.91
Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther (2010) 0.91